Australia's CSL posts a 7% drop in first-half profit
10/02/2026 20:49
Feb 11 (Reuters) - Australia's CSL Ltd CSL.AX reported a 7% fall in first-half profit, hit by softer plasma-therapy and albumin sales, while lifting its share buyback to $750 million. The biotechnology giant reported underlying net profit after tax attributable of $1.92 billion, on a constant currency basis, for the six months ended December 31, compared with $2.11 billion reported in the year-ago period. (Reporting by Roushni Nair and Sherin Sunny in Bengaluru; Editing by Alan Barona) ((Sherin.Sunny@thomsonreuters.com))
Recent news on Csl
See all newsEU Commission opens antitrust probe into Sanofi's flu vaccine campaign (updated)
EU Commission opens antitrust probe into Sanofi's flu vaccine campaign
Analysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
US military requires flu vaccine for some after outbreak in Texas training center
Corrected: BUZZ-Australian healthcare stocks hit a six-week high, acting as a primary hedge on ASX